Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Overview of attention for article published in Journal of Clinical Oncology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 7 news outlets
twitter: 37 X users

patent: 1 patent
guideline: 1 clinical guideline source

Readers on

mendeley: 103 Mendeley

So far, Altmetric has seen 51 X posts from 37 X users, with an upper bound of 192,157 followers.

今日の抄読会📘 プラチナベースの化学療法が効かなくなった再発子宮頸癌に対するBalstilimab (抗PD-1) とzalifrelimab (抗CTLA-4)併用の第2相試験皮膚のMMに使われるイピ(抗CTLA-4)・ニボ(抗PD-1) と似た、免疫チェックポイント阻害薬(ICI) 2剤の組み合わせ治療。 https:…

@PearlF That is exactly why new treatments are needed; see Bal+ zal data -ORR of 32.8% in PD-L1+ and 25.6% in all patients -ORRs and durability higher than approved therapies - mDuration of response not reached after 21 months https://t.co/v74mESBsDD

RT @DrMarilynHuang: Promising results from Bal/zal in recurrent cervical cancer #clinicaltrials #cervicalcancer ⁦@SylvesterCancer⁩ ⁦@JTrent…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 47 additional X posts.